Mangoceuticals Files Global Patent for MGX-0024 Avian Antiviral as H5N1 Protection Expands

Mangoceuticals, Inc. has filed a Patent Cooperation Treaty (PCT) international patent application on February 26, 2026, to establish comprehensive global patent protection for MGX-0024, a novel antiviral additive designed for animal feed and drinking water. The filing marks a significant milestone for the biotech company, following compelling clinical trial data demonstrating the technology's efficacy in preventing respiratory viral infections across multiple species, with particular relevance to the global poultry industry facing ongoing avian influenza threats.

The announcement comes amid heightened global concerns over avian influenza transmission, with H5N1 continuing to pose economic and public health risks worldwide. The timing of Mangoceuticals' international patent filing underscores the growing commercial and regulatory urgency surrounding preventive antiviral solutions for animal agriculture.

MGX-0024: Clinical Evidence and Current Patent Status

MGX-0024 represents a formulation designed to inhibit both respiratory and orally acquired viral infections in animals and birds through integrated feed and water delivery systems. The technology's development has been supported by compelling clinical validation data:

• Zero respiratory-related mortality demonstrated in trial cohorts of 29,000 birds
• Prophylactic efficacy against H5N1 avian influenza virus
• Dual delivery mechanism enabling integration into both feed and drinking water systems
• Multi-species application potential beyond poultry to other animal agriculture segments

Prior to the PCT filing, MGX-0024 secured U.S. patent protection, establishing domestic intellectual property rights. The company is simultaneously pursuing patent protection across strategically critical global markets:

• European Union
• Canada
• China
• India
• Australia
• Japan

This geographic diversification of patent applications reflects the global nature of the poultry supply chain and the international scope of avian influenza outbreaks. The PCT filing streamlines the process for securing patent rights across multiple jurisdictions while establishing an international priority date that protects against competitive disclosure during the examination period.

Market Context: Avian Health and Antiviral Landscape

The global poultry industry faces unprecedented pressure from recurring avian influenza outbreaks, which have resulted in significant economic losses through culling operations, supply chain disruptions, and reduced egg and meat production. H5N1 has demonstrated increasing ability to spread between flocks and across geographical regions, prompting industry stakeholders and governments to seek preventive interventions beyond traditional biosecurity measures.

The current competitive landscape for avian antiviral solutions remains limited, with most preventive strategies focused on vaccination programs and management practices rather than pharmaceutical or nutritional interventions. Mangoceuticals is positioning MGX-0024 as a complementary approach to existing prevention methods, potentially offering:

• Reduced reliance on antibiotics in poultry production
• Cost-effective prophylaxis compared to reactive treatment protocols
• Integration with existing farming infrastructure via established feed and water delivery systems
• Potential regulatory advantages as preventive rather than therapeutic intervention

The global animal health market, particularly the poultry segment, has demonstrated growing investment in preventive health solutions. Regulatory bodies including the FDA and EMA have shown increasing flexibility in approving novel animal health technologies, particularly those addressing emerging infectious disease threats. The H5N1 avian influenza situation has elevated the regulatory priority for effective prevention solutions, potentially accelerating approval pathways for validated interventions.

Competitor activity in the space remains fragmented, with most major animal health companies ($ZTS, for reference in the broader animal health sector) focusing on conventional vaccine development rather than feed-based antiviral additives. This positioning provides Mangoceuticals with potential first-mover advantages in the antiviral feed additive segment.

Investor Implications: IP Strategy and Commercial Potential

The PCT international patent filing represents a critical inflection point for Mangoceuticals' intellectual property strategy and commercial viability. Successfully securing global patent protection across major poultry-producing regions creates substantial barriers to competitive entry and establishes the foundation for licensing and commercialization partnerships.

Key investor considerations include:

Intellectual Property Strength: The filing of multiple patents across geographically diverse markets creates overlapping protection periods and complicates competitor efforts to design-around the technology. U.S. patent protection combined with pending approvals in the EU, China, and India—representing the world's largest poultry producers—establishes defensible market positions.

Commercial Opportunity Scale: The global poultry market exceeds $300 billion annually, with significant portions susceptible to H5N1 infection losses. Even modest market penetration for an effective prevention solution represents substantial revenue potential, particularly in premium or organic poultry segments where consumers accept additives.

Regulatory Pathway: The clinical trial data supporting zero mortality in large cohorts and specific H5N1 efficacy provides regulatory credibility for approval processes across major markets. Successful regulatory clearance in the EU or China would validate the technology globally and significantly accelerate commercial adoption.

Partnership Potential: Secured global patent rights create valuable negotiating positions for licensing agreements with major animal health companies, feed manufacturers, or poultry producers. Such partnerships could provide capital, distribution access, and credibility while reducing commercial execution risk for Mangoceuticals.

Risk Mitigation: Patent grants in major markets reduce uncertainty surrounding competitive threats and establish clear intellectual property monetization pathways. Rejection or limitations in specific jurisdictions could constrain commercial returns in those regions, though protection in the U.S. and EU alone would cover substantial market segments.

Forward-Looking Outlook

Mangoceuticals stands at a critical juncture in transitioning from research validation to commercial deployment of MGX-0024. The PCT international patent filing establishes the IP framework necessary for global market expansion, while clinical trial results provide the scientific foundation for regulatory approval and customer adoption. Success in securing patent protection across major markets, combined with regulatory clearances in key jurisdictions, would position the company to address one of animal agriculture's most pressing challenges while capturing meaningful market share in the global animal health sector. Investors should monitor developments in regulatory approval processes, licensing partnership announcements, and patent examination outcomes as indicators of near-term commercial momentum.